Clinical Trials Logo

Clinical Trial Summary

The INROAD is an investigator-driven, prospective, study in which patients undergoing coronary sinus reducer implantation (Reducer) for chronic refractory angina undergo evaluation of the index of microcirculatory resistance (IMR) at the time of implantation, and at 4 months follow-up


Clinical Trial Description

Refractory angina (RA) is a chronic condition (present for at least 3 months) of moderate-severe symptoms (Canadian class Cardiovascular Society [CCS] II-IV) due to coronary artery disease which cannot be adequately controlled by the combination of optimal medical therapy and coronary revascularization. The clinical impact in terms of quality of life, re-hospitalization and socio-health costs is extremely negative. In this context, the therapeutic goals are primarily the management of the symptom and improvement the patient's quality of life. The unpaid therapeutic demand of these patients has brought out a large number of medical and interventional treatments, including the coronary sinus reduction system (REDUCER). Numerous clinical studies and registries have been carried out and they proved both the efficacy and safety in the use of REDUCER. The physiological mechanism that are supposed to be behind the antianginal effect of coronary sinus intervention are essentially two: 1. Redistribution of coronary flow from the subepicardium to the subendocardium. 2. Coronary neoangiogenesis In both cases, the primum movens of the Reducer's therapeutic mechanism is attributable to the increase in venous pressure due to narrowing of the coronary sinus. Nevertheless, this mechanism of action is theoretical and has never been objectively tested. The evaluation of microcirculatory resistance by IMR before and after REDUCER implantation could be the most effective way to confirm this hypothesis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05174572
Study type Interventional
Source Consorzio Futuro in Ricerca
Contact
Status Active, not recruiting
Phase N/A
Start date December 3, 2021
Completion date March 31, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05711849 - Assessing the Safety and Effectiveness of Intracoronary Stem Cells in Patients With Refractory Angina Phase 2
Withdrawn NCT03438500 - Cardiac Shock Wave Treatment in Patients With Reduced Coronary Flow Reserve N/A
Recruiting NCT01711099 - Efficacy of Extracorporeal Shockwave Myocardial Revascularization N/A
Active, not recruiting NCT03039751 - Adenovirus Vascular Endothelial Growth Factor D (AdvVEGF-D) Therapy for Treatment of Refractory Angina Pectoris Phase 2
Suspended NCT01567592 - Extracorporeal Shockwave Therapy for the Treatment of Chronic Angina Pectoris Phase 1
Active, not recruiting NCT01241968 - Extracorporeal Shock Wave Therapy for the Treatment of Ischemic Heart Disease Phase 2
Recruiting NCT02499250 - Effect of Daily Remote Ischemic Conditioning on the Life Quality of Refractory Angina Pectoris Patients N/A
Completed NCT01219218 - Extracorporeal Shockwave Therapy for the Treatment of Advanced Angina Pectoris Phase 1
Active, not recruiting NCT01567644 - Extracorporeal Shockwave Therapy for the Treatment of Refractory Chronic Angina Pectoris Phase 1
Completed NCT00662727 - Extracorporeal Shockwave Therapy for the Treatment of Refractory Angina Pectoris Phase 2
Completed NCT04121845 - CoROnary SinuS Reducer implantatiOn for ischemiA reDuction N/A
Recruiting NCT04915157 - Efficacy of Spinal Cord Stimulation in Patients With Refractory Angina Pectoris N/A
Completed NCT01508910 - Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina Phase 3